RORC1 Regulates Tumor-Promoting &quot;Emergency&quot; Granulo-Monocytopoiesis by Strauss, L. et al.
ArticleRORC1 Regulates Tumor-Promoting ‘‘Emergency’’
Granulo-MonocytopoiesisGraphical AbstractHighlightsd RORC1 drives cancer-related myelopoiesis in response to
colony-stimulating factors
d RORC1+ myeloid cells are a hallmark of tumor-promoting
emergency myelopoiesis
d RORC1 ablation in the hematopoietic compartment prevents
generation of MDSCs and TAMs
d RORC1 ablation in the hematopoietic compartment prevents
tumor developmentStrauss et al., 2015, Cancer Cell 28, 253–269
August 10, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.ccell.2015.07.006Authors
Laura Strauss, Sabina Sangaletti,
Francesca Maria Consonni, ..., Claudio
Tripodo, Mario P. Colombo, Antonio
Sica
Correspondence
antonio.sica@humanitasresearch.it
In Brief
Strauss et al. show that RORC1
orchestrates myelopoiesis and supports
tumor-promoting innate immunity.
Importantly, ablation of RORC1 in the
myeloid compartment inhibits tumor
growth and metastasis, suggesting a
cancer therapeutic approach.
Cancer Cell
ArticleRORC1 Regulates Tumor-Promoting
‘‘Emergency’’ Granulo-Monocytopoiesis
Laura Strauss,1 Sabina Sangaletti,4 Francesca Maria Consonni,2 Gabor Szebeni,1 Sara Morlacchi,1 Maria Grazia Totaro,1
Chiara Porta,2 Achille Anselmo,1 Silvia Tartari,1 Andrea Doni,1 Francesco Zitelli,2 Claudio Tripodo,3 Mario P. Colombo,4
and Antonio Sica1,2,*
1Department of Inflammation and Immunology, Humanitas Clinical and Research Center, 20089 Rozzano, Milan, Italy
2Department of Pharmaceutical Sciences, Universita` del Piemonte Orientale ‘‘Amedeo Avogadro,’’ Via Bovio 6, 28100 Novara, Italy
3Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy
4Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milan, Italy
*Correspondence: antonio.sica@humanitasresearch.it
http://dx.doi.org/10.1016/j.ccell.2015.07.006SUMMARYCancer-driven granulo-monocytopoiesis stimulates expansion of tumor promoting myeloid populations,
mostly myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs). We identi-
fied subsets of MDSCs and TAMs based on the expression of retinoic-acid-related orphan receptor
(RORC1/RORg) in human and mouse tumor bearers. RORC1 orchestrates myelopoiesis by suppressing
negative (Socs3 and Bcl3) and promoting positive (C/EBPb) regulators of granulopoiesis, as well as the
key transcriptionalmediators ofmyeloid progenitor commitment and differentiation to themonocytic/macro-
phage lineage (IRF8 and PU.1). RORC1 supported tumor-promoting innate immunity by protecting MDSCs
from apoptosis, mediating TAM differentiation and M2 polarization, and limiting tumor infiltration by mature
neutrophils. Accordingly, ablation of RORC1 in the hematopoietic compartment prevented cancer-driven
myelopoiesis, resulting in inhibition of tumor growth and metastasis.INTRODUCTION
Immunologic stress, such as infection and cancer, modifies
the magnitude and composition of the hematopoietic output, a
feature of immune regulation defined as ‘‘emergency’’ hemato-
poiesis, to guarantee proper supply of immune cells to increased
demand (Ueha et al., 2011). Tumors can reprogram myeloid
cells to promote disease progression (Sica and Bronte, 2007).
However, the molecular pathways guiding cancer-driven ‘‘emer-
gency’’ myelopoiesis remain largely unknown. Colony-stimu-
lating factors (CSFs) are major orchestrators of hematopoietic
development. Among these, granulocyte CSF (G-CSF) and
granulocyte-macrophage CSF (GM-CSF) drive ‘‘emergency’’
myelopoiesis by securing supply of neutrophils and macro-
phages from bone marrow (BM) and hematopoietic stem cellSignificance
Preclinical data show that MDSCs and TAMs orchestrate tumo
therapeutic targets. MDSC and TAM generation is tightly ass
in cancer, defined as ‘‘emergency hematopoiesis.’’ Here we rep
in tumor bearers, in response to colony-stimulating factors (G
myeloid cells mark advanced cancer inflammation. We demon
impairs tumor development and the generation of suppressive
ized TAMs. Thus, inhibition of RORC1-dependent myelopoie
induction of the tumor-promoting host macro- and micro-envniches (HSCs) (Metcalf, 2008; Ueha et al., 2011). Further, the
macrophage CSF (M-CSF) promotesmacrophage differentiation
from medullar precursors and differentiation of tissue macro-
phages involved in tissue homeostasis (Hume and MacDonald,
2012) and tumor progression (Qian and Pollard, 2010). Recent
studies reveal that monocytic and granulocytic myeloid-derived
suppressor cells (M-MDSCs and PMN-MDSCs, respectively)
and tumor-associated macrophages (TAMs), the major myeloid
populations associated with cancer development (Sica and
Bronte, 2007), differentiate from a common myeloid progenitor
(CMP) (Gabrilovich et al., 2012). Importantly, reciprocal regula-
tion of macrophage versus neutrophil/granulocyte differentiation
might control tissue homeostasis. Depletion of tissue macro-
phages leads to exacerbated G-CSF-mediated granulopoiesis
(Gordy et al., 2011; Goren et al., 2009), and tissue macrophagesr-promoting conditions, suggesting these cells as attractive
ociated with the altered hematopoietic output that occurs
ort that RORC1 is a key driver of emergency hematopoiesis
-CSF, GM-CSF, and M-CSF), and that RORC1-expressing
strate that ablation of RORC1 in the myeloid compartment
MDSCs while promoting generation of antitumor M1-polar-
sis may represent a therapeutic approach to prevent the
ironments.
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regulate HSC niche homeostasis (Chow et al., 2011; Winkler
et al., 2010). Thus, investigation of the molecular networks that
dictate this reciprocal regulation appears to be crucial, as it
may affect tissue homeostasis during cancerogenesis.
G-CSF-induced granulopoiesis is mediated through the
transcription factors c-EBPb (Akagi et al., 2008) and STAT3
(Zhang et al., 2010), whereas M-CSF supports monocyte differ-
entiation through the transcription factors PU.1 and IRF8 (Fried-
man, 2007). Of relevance, interleukin-17A (IL-17A) promotes
G-CSF- and stem-cell-factor-mediated neutrophilia (Liu et al.,
2010) and supports G-CSF-driven ‘‘emergency’’ myelopoiesis
(Schwarzenberger et al., 2000).
Despite the fact that IL-17 expression in cancer has been so
far mainly restricted to the adaptive immunity (Iwakura et al.,
2011) and its role in cancer remains controversial (Toomer and
Chen, 2014), TAMs and MDSCs produce the Th17-driving
cytokines TGFb and IL-6 (Zamarron and Chen, 2011), and IL-
17-expressing cells with macrophage morphology have been
described in cancer patients (Zhu et al., 2008). Although the
Th17 response is controlled by the orphan nuclear receptor ret-
inoic-acid-related orphan receptor gamma (RORg) full-length
protein (RORC1) and the RORCgt splice variant (RORC2) (Ivanov
et al., 2006), the signaling pathways that drive IL-17-producing
innate immune cells have been poorly investigated. IL-17A-ex-
pressing myeloid cells have been reported in inflammation (Tay-
lor et al., 2014; Zhu et al., 2008; Zhuang et al., 2012). In arthritis
patients, mast cells express a dual RORC1/IL-17A fingerprint in
response to TLR4 ligands (Hueber et al., 2010), and a population
of RORgt-expressing neutrophils that produce IL-17 was identi-
fied in fungal infection (Taylor et al., 2014). We explored the role
of the IL-17/RORC1 axis in myeloid lineage differentiation and
commitment associated with cancer development.
RESULTS
Divergent RORC1/IL-17A Fingerprint in
Tumor-Associated Myeloid Cells
To clarify the role of IL-17A+ innate immune cells in tumor
progression, we screened the myeloid compartment of fibro-
sarcoma (MN/MCA1)-bearing C57BL/6 mice. A tumor volume
of <1.5 cm3 and few lung metastases (fewer than five), at days
21–23 after tumor cell injection, was defined as early-stage dis-
ease (ED), whereas tumors larger than 2 cm3 and a higher num-
ber of lung metastases (more than 15; days 25–28) was defined
as advanced-stage disease (AD) (Figure S1). In AD, few blood
and spleen CD45+CD3+ T cells expressed IL-17A (data not
shown), whereas IL-17A was significantly expressed by CD45+
CD3 cells in the blood (30% ± 3%) and spleen (12% ± 1.5%)
(Figure 1A). Few CD45+CD3 cells expressed IL-17A in non-
tumor bearers (NTs) and ED, suggesting that IL-17A+ myeloid
cells mark advanced cancer-associated inflammation. FACS
analysis of theCD45+CD3 cell pool confirmed that Gr1+CD11b+
MDSCs represent the major splenic myeloid population in AD
(Figure 1B), comprising a predominant polymorphonuclear
CD11b+Gr1+Ly6GhighLy6Clow (PMN-MDSC) population and
side monocytic CD11b+Gr1+Ly6ChighLy6Glow (M-MDSC) and
CD11b+F4/80+ macrophage populations. IL-17A was signifi-
cantly expressed by PMN-MDSCs in the blood and spleen
of AD mice (Figure 1C), although these cells failed to release254 Cancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc.IL-17 in response to degranulating signals, including CD16/32
(FCII/III) antibody-mediated cross-linkage and C5a (data not
shown) (Mantovani et al., 2011). In contrast, IL-17A was poorly
or not expressed by M-MDSCs (Figure 1C) and CD11b+F4/80+
macrophages (data not shown). RORC1 and its splice variant
RORC2 are master regulators of IL-17A gene transcription
in Th17 cells (Ivanov et al., 2006), innate lymphocytes (Sawa
et al., 2010), gd T cells (Gray et al., 2011), and natural killer
T cells (Rachitskaya et al., 2008). Hence, we tested by FACS
whether IL-17 expression in myeloid cells was associated
with RORC1. In keeping with IL-17A expression, the majority
of blood and spleen PMN-MDSCs from AD mice expressed
RORC1, while its expression was restricted to a minor subset
of IL-17A M-MDSCs (Figure 1D, left). Nevertheless, as
compared to PMN-MDSCs, M-MDSCs expressed higher levels
of RORC1, estimated as mean fluorescence intensity (MFI) (Fig-
ure 1D, right). It is noteworthy that RORC1 was highly expressed
by splenic IL-17ACD11b+F4/80+ macrophages in ADmice (Fig-
ure 1E), by F4/80+ TAMs (>90%) and thyoglicollate-elicited peri-
toneal macrophages (PECs) from both tumor-free (NT-PEC) and
AD (AD-PEC) mice (Figure 1E).
To corroborate the evidence that ED stages already pro-
mote emergency hematopoiesis, we performed histopatholog-
ical and immunohistochemical analysis of both spleens and BM
frommice bearing early- and late-stage tumor (Figure 2A). Histo-
pathological analysis of the BM parenchyma of wild-type (WT)
and Rorc1/ tumor-free and tumor-bearing mice (including ED
and AD tumor stages) showed a significant expansion of the
granulocytic compartment (Figure 2A, top), which associated
with a progressive contraction of the erythroid colonies (blue ar-
rows) and with signs of dysmegakaryopoiesis (i.e., megakaryo-
cytes with bulbous and/or hypolobated nuclei and prominent
pleiomorphism; red arrows). Notably, at late time points (AD),
theBMgranulocytic hyperplasia of tumor-associated emergency
hematopoiesis was characterized by the enrichment in immature
myeloid precursors (Figure 2A, top, dashed lines), which were
more conspicuous in WT than in Rorc1/ mice. As expected,
tumor-freemice showed a normal composition of the hematopoi-
etic parenchyma in theBMwithpreservedmyeloid/erythroid ratio
and normal maturation of the myeloid elements. Spleen histopa-
thology performed on the same animals demonstrated signs of
tumor-associated emergency hematopoiesis in the spleen
parenchyma of ED and AD tumor-bearing WT and Rorc1/
mice, in the form of red pulp hyperplasia underlying splenomeg-
aly (Figure 2A, bottom). The enhanced myelopoiesis of WT mice
featured the progressive (i.e., from ED to AD) accumulation of
clusters of morphologically immature granulocytes (Figure 2A,
bottom, arrows and dashed lines; right H&E insets) that inter-
mingled with erythroid precursor islets, megakaryocytes, and
polymorphonuclear granulocytes. Despite a comparable degree
of red pulp hyperplasia due to the consistent increase in poly-
morphonuclear granulocytes, erythroid precursors, and mega-
karyocyte clusters, Rorc1/ mice showed less clusters of
morphologically immature myeloid cells as compared with their
WT counterparts (Figure 2A, bottom, arrows and dashed lines;
right H&E insets). Immunohistochemical analysis of the MDSC-
associated IL-4R marker highlighted IL-4R+ myeloid cells with
monocytoid or granulocytic morphology populating the myeloid
cell aggregates differently enriched within the expanded red
Figure 1. Myeloid-Specific IL-17A+/RORC1+
Cells Mark Advanced Cancer-Associated
Inflammation
(A) Expression of IL-17A by CD45+CD3 hemato-
poietic cells in blood (left) or spleens (right) from
tumor-free (NT) or MN/MCA1-bearing mice, at
both early tumor disease (ED) and advanced
tumor disease (AD). Mean percentages ± SEM of
IL-17A+ cells within the CD45+CD4CD3 gate
were measured by fluorescence-activated cell
sorting (FACS).
(B) Myeloid subsets in spleens from tumor-
bearing mice. Mean percentages ± SEM of
Gr1+CD11b+ (total MDSCs), CD11b+Gr1+Ly6C+
Ly6Glow (M-MDSCs), CD11b+Gr1+Ly6G+Ly6Clow
(PMN-MDSCs) and CD11b+F4/80+ cells in spleen
from NT, ED, or AD mice measured within the
CD45+ gate.
(C) Mean percentages ± SEM of IL-17A-express-
ing M-MDSCs and PMN-MDSCs in blood or
spleens from NT, ED, or AD mice.
(D) Mean percentages and MFI ± SEM of RORC1-
expressing M-MDSCs and PMN-MDSCs in blood
or spleens from NT or tumor-bearing mice.
(E) RORC1-expressing splenic CD11b+F4/80+
cells obtained from NT, ED, and AD mice (left) or
RORC1-expressing PECs obtained from NT
(NT-PECs) and AD (AD-PECs) mice and RORC1-
expressing TAMs isolated from AD tumors
(MN/MCA1) (right). Results are shown as mean
percentages ± SEM. Expression of IL-17A and
RORC1 in myeloid cells was determined within the
CD11b+CD45+ gate. Results of a representative
experiment of six independent experiments with
sixmice/group are shown. Statistical analysis: *p <
0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
See also Figure S1.pulp of tumor-bearing WT and Rorc1/ mice (Figure 2A). Over-
all, these results demonstrate that Rorc1/ mice effectively
instruct BM and splenic emergency hematopoiesis along cancer
development while displaying a defective induction of specific
MDSC-related myeloid populations.
With the gating strategy used to determine IL-17A and RORC1
shown in Figure 2B, our results suggest that RORC1 expres-
sion is uncoupled from IL-17A in the monocytic/macrophage
compartment, while it is co-expressed in the granulocytic cells
of tumor-bearingmice. To validate this finding in cancer patients,
we analyzed the MDSC populations in PBMCs from healthy do-
nors (HDs; n = 10) or patients with advanced colorectal cancer
(CRC; stage II/III; n = 10) using the gating strategy of Figure 2C.
It is noteworthy that the number of RORC1+ M-MDSCs (HLA-
DRlow/CD14+CD33high) and PMN-MDSCs (HLA-DRlow/CD15+
CD33high) increased in CRC patients and dominated in the
human PMN-MDSC subset (Figure 2D). Expansion of MDSC
populations in cancer patients was paralleled by an increased
number of circulating neutrophils and monocytes (Figure 2D).
Also in analogy to the murine setting (Figure 1D), the human
M-MDSC population showed higher mean fluorescence
intensity of RORC1+. In contrast, IL-17A was detected neither
in human blood M-MDSCs nor in PMN-MDSCs (data notshown). These results indicate that expression of RORC1 by
myeloid subsets constitutes a hallmark of tumor-promoting
‘‘emergency’’ myelopoiesis.
RORC1 Promotes Expansion of MDSCs and TAMs
To investigate the in vivo relevance of RORC1-expressing
myeloid cells, we transplanted donor RORC1-deficient BM
cells into lethally irradiated C57BL/6 WT recipient mice
(Rorc1/>WT), to be compared to WT>WT mice. Eight weeks
later, mice were injected with MN/MCA1 cells and monitored
for tumor development. Tumor growth and metastasis were
significantly reduced in Rorc1/>WT mice (Figure 3A). The
effect of RORC1 deficiency in BM cells was tested in two
additional tumor models. Rorc1/ BM was transplanted into
mouse mammary tumor virus-polyoma middle T antigen
(MMTV-PyMT; a spontaneous mammary carcinoma [Guy et al.,
1992]) transgenic mice and into C57BL/6 mice that were
exposed to methylcholanthrene-induced cancerogenesis and
subsequently developed fibrosarcoma (Stutman, 1974) (Fig-
ure 3B). Consistently, RORC1 deficiency in the BM resulted in tu-
mor growth inhibition in both models (Figure 3B). FACS analysis
(data not shown) confirmed the IL-17/RORC1 expression pattern
observed in the MN/MCA1 model (Figure 1). Rorc1/>WTCancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc. 255
(legend on next page)
256 Cancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc.
tumor-bearing mice showed a significant reduction of splenic
M-MDSCs and PMN-MDSCs, in comparison to WT>WT mice
(Figure 3C). To estimate the suppressive activity of M-MDSCs,
we activated cells with IFN-g (Gabrilovich et al., 2012), loaded
them with ovalbumin, and then co-cultured them for 3 days
with total splenocytes purified from OT-1 transgenic mice ex-
pressing the T cell receptor specific for the ovalbumin antigen.
Rorc1/ M-MDSCs displayed reduced suppressive activity,
estimated as proliferation of co-cultured OT1 splenocytes (Fig-
ure 3D). It is noteworthy that, at the tumor site, we observed an
increase of PMN-MDSCs (Figure 3E), as opposed to a significant
decrease of CD11b+Ly6ClowF4/80+ TAMs (Figure 3F). Histologi-
cal analysis of spleens from Rorc1-deficient tumor bearers
showed a dramatic reduction in IL-4R+ MDSCs (Marigo et al.,
2010) and strongly reduced expression of IL-17A (Figure 3G) in
comparison to WT counterpart. These results are further confir-
mative of the IL-4R expression analyses onWT andRorc1/BM
(Figure 2A) and imply that RORC1 promotes the expansion
of splenic MDSCs and TAMs. To confirm this conclusion, we
treated tumor-free or MN/MCA1-bearing WT mice with the
RORC1 agonist SR1078 (Kojetin and Burris, 2014). SR1078
increased the AD lung metastatic burden (Figure S2A), as well
as splenic M-MDSCs and PMN-MDSCs (Figure S2B, left).
Despite the fact that CD11b+F4/80+ macrophages were not
modified (data not shown), SR1078 increased RORC1 expres-
sion in splenic macrophages, as well as in M-MDSCs and
PMN-MDSCs (Figure S2B). By contrast, IL-17A expression
was selectively induced in PMN-MDSCs (Figure S2B, right). Of
note, SR1078 did not affect steady-state myelopoiesis in tu-
mor-free mice (Figure S2C), confirming RORC1 as a positive
regulator of myelopoiesis in cancer.
To explain the reduction of MDSCs in Rorc1/ tumor-bearing
mice, we considered two possible mechanisms: RORC1 regu-
lates the differentiation of hematopoietic precursors in the BM
(Figure 4) and/or RORC1 regulates the survival and maturationFigure 2. Effects of RORC1 on Emergency Hematopoiesis Associated
(A). Top: BM histopathological analysis of WT (left) and Rorc1/ (right) tumor-f
showing the progressive changes in BM hematopoietic parenchyma along tum
hematopoietic composition with no detectable differences between WT and Ror
myeloid granulocytic lineage, which was paralleled by the contraction of the ery
similarly observed in WT and Rorc1/ mice. In AD samples, the myeloid pool e
myeloid cell clusters (dashed lines), which was consistent with the enhanced mye
immature myeloid cell clusters characterizing AD samples were more prominent
Bottom: spleen histopathological analysis ofWT (left) andRorc1/ (right, compos
panels; AD, lower composite panels) mice showing the progressive increase in red
In tumor-free mice, white pulp (WP) areas are predominant over RP, the latter be
yocytic elements (upper H&E panels and upper H&E insets). In ED and AD samples
foci. In particular, the RP WT mice showed an increase in immature myeloid cell
granulocytic or monocytoid morphology (left middle and lower H&E insets, arrows
Rorc1/ mice, despite a comparable degree of RP hyperplasia mainly conseq
clustering, foci of morphologically immature myeloid cells were less evident (right
RP myeloid cell clusters that were differently expanded in WT and Rorc1/ m
marker IL-4R were detected (IHC insets, red signal).
(B) Gating strategy used to determine the different mouse myeloid subsets.
(C) Gating strategy used to determine the different human myeloid subsets.
(D) Cytofluorimetric analysis of RORC1 expression in the circulating MDSC subset
was performed on PBMCs, and analysis of neutrophils and monocytes was
DRCD332+CD14+), PMN-MDSCs (HLA-DRCD332+CD15+), monocytes (HLA-D
CD16+CD33+) in blood from healthy donors (HD; n = 10) and CRC patients (n = 10
test). Below, a representative flow-cytometry analysis of RORC1+M-MDSCs andof MDSCs (Figure S3). We first analyzed by FACS the commit-
ment of common hematopoietic progenitors in tumor-bearing
WT>WT and Rorc1/>WT chimeras. Although in the spleen
few Linc-kit+Sca-1+ (LSK) cells were measured (data not
shown), LSK cells were significantly increased in the BM from
Rorc1/>WT mice (Figure 4A). Analysis of myeloid progenitors
revealed increased number of CMPs in the BM of Rorc1/>WT
chimeras and, in accordance, a decrease of granulocyte/macro-
phage progenitors (GMPs) (Figure 4A). These findings reveal a
blockage in differentiation of early hematopoietic progenitors in
Rorc1/>WT chimeras and suggest a relevance of RORC1
directly in the BM during the early steps of myeloid cell differen-
tiation. Corroborating this hypothesis, RORC1was expressed by
immature (c-kit+) granulocytes andmonocytes in the BMof naive
mice (Figure 4B). In the same myeloid cell subsets, IL-17 was
found produced mainly by immature neutrophils (Figure 4B).
Next, we tested the in situ expression of IL-17A and RORC1 in
BM parenchyma of patients undergoing a biopsy for staging
of Hodgkin’s lymphoma. Consistently, IL-17A staining was local-
ized within myeloid cells with immature morphology, within the
precursor-rich areas lining the bone trabeculae (Figure 4C, black
arrows). By contrast, mature granulocytes with segmented
nuclei barely expressed or did not express IL-17A. Indeed, a
neat decreasing gradient was observed in IL-17A expression
from para-trabecular areas rich in precursors toward inter-
trabecular spaces mainly populated by mature elements (Fig-
ure 4C). Notably, double-marker immunohistochemical analysis
confirmed that IL-17A+ hematopoietic cells did not correspond
to Th-17 cells, as they were distinct from the CD3+ T elements
populating the BM niche (Figure 4D, black arrows). Within
the same BM hematopoietic parenchyma, RORC1 (RORg)
expression was detected mostly in myeloid cells with combined
cytoplasmatic and nuclear localization (Figure 4E, black arrows).
These results in human samples further support that the RORC1/
IL-17A program takes part in the regulation of the precursorwith Cancer Development
ree (NT) and tumor-bearing mice with early (ED) and advanced (AD) disease,
or development in the two strains. While tumor-free mice displayed a normal
c1/ strains, ED and AD BM samples showed a progressive expansion of the
throid (blue arrows) and megakaryocytic (red arrows) compartments and was
xpansion was also characterized by the increase in morphologically immature
lopoietic activitiy of stress-adapted (i.e., cancer-associated) myelopoiesis. The
in WT than in Rorc1/ mice. Original magnifications of H&E panels are 3400.
ite panels) tumor-free (upper panels) and tumor-bearing (ED,middle composite
pulp (RP) hematopoietic function along tumor development in the two strains.
ing mainly populated by erythroid cells with scattered myeloid and megakar-
, RP hyperplasia was evident and consequent to the increase of hematopoietic
figures (left middle and lower H&E panels, arrows and dashed lines) showing
), along with an increase in megakaryocyte and erythroid precursor clusters. In
uent to megakaryocyte and polymorphonuclear granulocyte expansion and
middle and lower H&E panels and insets, arrows and dashed lines). Within the
ice, cells with granulocytic or monocytoid morphology expressing the MDSC
s, neutrophils, andmonocytes from CRC patients as indicated. MDSC analysis
carried out in whole blood. Mean percentages ± SEM of M-MDSCs (HLA-
R+CD14+CD15low/CD16CD332+), and neutrophils (HLA-DRCD14CD15+
) are shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t
RORC1+PMN-MDSCs from cancer patients is also shown.
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compartment during myelopoiesis. To test whether RORC1
regulates myelopoiesis, lineage-negative (Lin) cells isolated
from WT and Rorc1/ BM were treated in vitro with G-CSF
or GM-CSF and tested, 5 days later, for granulocyte or mono-
cyte differentiation by flow cytometry (Figure 4F). In response to
GM-CSF, Lin cells from Rorc1/ mice failed to differentiate in
macrophages, displaying increased differentiation into GR-1high
granulocytes. On the contrary, G-CSF treatment resulted in
reduced GR-1high granulocyte production by RORC1/ Lin
cells. This contrasts with the steady-state condition, where in
absence of any specific stimulus the rate of differentiation of
Lin cells was identical between WT and Rorc1/ BM sources.
These results indicated a key role of RORC1 in the myelopoietic
activity of G-CSF and GM-CSF. Figure S3A underlies the
different effects of G-CSF and GM-CSF on the differentiation
of Ly6G+ subsets, indicating that GM-CSF promotes a larger
expansion of double Ly6G+Ly6C+ monocytic cells.
We next determined whether RORC1 might control MDSC
survival (Sinha et al., 2011) and maturation. Small differences
were observed in survival of WT versus Rorc1/ BM-derived
MDSCs at steady-state conditions (medium) (Figure S3B). In
contrast, increased AnxV+ binding was observed in both
M-MDSCs and PMN-MDSCs after 48 hr, which was reduced in
the presence of either tumor supernatant (TSN) or combination
of GM-CSF/G-CSF in both subsets (Figure S3B), indicating
that RORC1 is crucial for MDSC survival. The protective role of
both TSN and GM-CSF/G-CSF against apoptosis was partially
lost in RORC1-deficient M-MDSCs, while RORC1-deficient
PMN-MDSCs suffered a massive apoptosis (Figure S3B). These
results confirm the protective role of RORC1 in CSF-mediated
M-MSDC and PMN-MDSC survival, highlighting a tighter depen-
dence of PMN-MDSC survival from RORC1 expression levels.
Neutrophil activation and maturation is paralleled by upre-
gulation of the FCgII and FCgIII receptors (CD32 and CD16,
respectively) (Hogarth, 2002) and of the complement C5a re-
ceptor (C5aR) (Guo and Ward, 2005). Splenic PMN-MDSCs
from WT>WT tumor bearers expressed lower CD16/CD32 and
C5aR levels than did PMN-MDSCs from Rorc1/>WT mice
(Figure S3C). Furthermore, WT splenic immature PMN-MDSCs
expressed lower levels of CD16/CD32 and C5aR, as opposed
to higher RORC1, when compared to mature thioglycollate-eli-Figure 3. Role of RORC1 in the Expansion of MDSCs and TAMs during
(A) MN/MCA1 cells were injected into the indicated hematopoietic reconstitutedm
monitored. At day 28, mice were sacrificed, the weight of the tumors (g) was esti
measured (right). Data are shown are the mean ± SEM of at least 12 mice/group
(B) Rorc1/ BMwas transplanted into MMTV-PyMT transgenic mice (left) or C57
fibrosarcoma (right). Mean tumor volumes (cm3) ± SEM from six WT>WT and R
***p < 0.001 (Student’s t test).
(C) Mean percentages ± SEM of M-MDSCs and PMN-MDSCs in spleens from
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(D) Decreased antigen-specific (OVA) suppressive activity of Rorc1/M-MDSCs
the mean ± SEM of a representative experiment done in triplicate. Statistical ana
(E) Mean percentages ± SEM of M-MDSCs and PMN-MDSCs in primary AD tumo
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(F) Mean percentages ± SEM of F4/80+ TAMs in primary tumors from WT>W
Rorc1/>WT chimeras (white bar) is represented as relative value as compared t
of six independent experiments, with n = 6 mice per group is shown. Statistical
(G) Histological analysis of IL-17A+ and IL-4R+ in the splenic MDSC population i
See also Figure S2.cited neutrophils (Neu-PECs) (Figure S3D). These observations
indicate that RORC1 might suppress neutrophil maturation,
favoring immature PMN-MDSCs to support tumor promotion.
RORC1 Controls Critical Regulators of Myelopoiesis
To determine the tumor-derived factor/s that activate RORC1,
we analyzed MN/MCA1 supernatants from AD mice for myeloid
growth factors. TSNs were enriched in G-CSF, GM-CSF, and
M-CSF and partially in IL-1b (Figure 5A). Of note, 48 hr of treat-
ment with either a combination of GM-CSF and G-CSF or TSN
induced IL-17A expression in BM-derived PMN-MDSCs and,
to a lower extent, in M-MDSCs (Figure 5B, left). BM-derived
M-MDSCs and PMN-MDSCs expressed basal RORC1 levels
(Figure 5B, right), plausibly induced by GM-CSF and G-CSF
used for their in vitro generation (Peranzoni et al., 2010), which
was increased by combination of GM-CSF and G-CSF (Fig-
ure 5B, right). Confocal microscopy demonstrated that RORC1
expression and nuclear translocation was induced in naive
PECs challenged for 72 hr with lipopolysaccharide (LPS), IL-
1b, G-CSF, GM-CSF, and M-CSF, but not by IFN-g (Figure 5C)
or IL-6 (data not shown). Of note, we found increased levels of
G-CSF and GM-CSF in the sera of AD mice (data not shown),
as compared to ED mice, suggesting that RORC1-dependent
emergency hematopoiesis is controlled by the extent of can-
cer-associated inflammation.
Finally, we determined the mRNA levels for RORC1 and
RORC2 (Ivanov et al., 2006; Yang et al., 2008) in PECs and in thy-
mocytes (Sun et al., 2000) from healthy WT mice (Figure S4A). It
is noteworthy that LPS-stimulated (72 hr) PECs expressedRorc1
mRNA levels similar to those of WT thymocytes, but not Rorc2
mRNA. These data confirm that in cancer, the monocyte-macro-
phage lineage expresses a selective RORC1 fingerprint unlinked
from IL-17A, whereas the granulocyte/neutrophil lineage ex-
presses a dual RORC1/IL-17A signature. In support of RORC1
as a key driver of ‘‘emergency’’ granulo-monocytopoiesis, BM-
CD11b+Gr1+ granulocytes and BM-CD11b+Ly6C+ monocytes
from both LPS- and M-CSF-treated mice significantly increased
RORC1 expression (Figure S4B).
To determine the in vivo role of myeloid growth factor/s, we
treated MN/MCA1-bearing mice with neutralizing antibodies to
G-CSF, GM-CSF, or the M-CSF receptor (M-CSFR/CSFR1)Tumor-Driven Emergency Myelopoiesis
ice. Starting from day 14 after MN/MCA1 cell injection, tumor volume (cm3) was
mated (left), and the number and weight of macroscopic lung metastases was
. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
Bl/6 mice, which were subsequently exposed to methylcholanthrene to induce
orc1/>WT chimeras are shown. Statistical analysis: *p < 0.05, **p < 0.01,
WT>WT and Rorc1/>WT tumor (MN/MCA1) bearers. Statistical analysis:
in response to IFN-g at different MDSC:OT1 splenocyte ratios. Data shown are
lysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
rs (MN/MCA1) from WT>WT and Rorc1/>WT mice (AD). Statistical analysis:
T and Rorc1/>WT tumor bearers (MN/MCA1). Myeloid cell percentage in
oWT>WT chimeras (100%) (black bar). Data from a representative experiment,
analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
n WT and Rorc1/ tumor-bearing mice.
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Figure 4. RORC1 Regulates Myeloid Commitment of BM Precursors
(A) Frequency of hematopoietic stem cells (LSK) andmyeloid progenitors (CMP, GMP, andMEP) in the BMofWT andRorc1/mice. Mean percentages ± SEM is
shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 n = 6 (Student’s t test).
(B) Flow-cytometry analysis for the expression of RORC1 and IL-17 in different myeloid cells identified by staining of BM cells with monoclonal antibodies to
CD11b, CD117, GR-1, and F4/80. For RORC1 expression, BMcells fromRorc1/micewere set as a negative control. Immature granulocytes (myeloblasts) were
identified according to their co-expression of GR-1 and c-kit. Mature granulocytes were GR-1high and c-kit, whereas monocytes/macrophages were
CD11b+Gr-1F4/80+. For further checking of their phenotype, these populations were sorted and stained with Giemsa. Representative pictures are shown.
(legend continued on next page)
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(Hume and MacDonald, 2012). Inhibition of G-CSF and GM-CSF
limited the accumulation of splenic PMN-MDSCs with no effect
on M-MDSCs (Figure 5D, left). In contrast, the anti-CSFR1 anti-
body decreased the number of F4/80+ spleen macrophages
whereas, surprisingly, it induced a strong increase in splenic
PMN-MDSCs. At contrast, the anti-G-CSF antibody significantly
increased the CD11b+F4/80+ spleen macrophages. Confirming
the relevance of myelopoiesis to cancer inflammation, neutrali-
zation of GM-CSF, G-CSF, or M-CSFR resulted in inhibition of
tumor growth and metastasis (Figure 5D, center and right).
These findings suggest a reciprocal antagonistic regulation of
the polymorphonuclear and monocytic lineages in CSF-driven
‘‘emergency’’ myelopoiesis in cancer.
To shed light on themechanisms of RORC1-driven emergency
myelopoiesis, we evaluated positive and negative transcriptional
regulators in BM and spleens from WT>WT and Rorc1/>WT
tumor bearers. CCAAT/enhancer binding protein b (C/EBPb) is
amajor positive regulator of G-CSF- andGM-CSF-driven ‘‘emer-
gency’’ myelopoiesis (Akagi et al., 2008), whereas C/EBPa ap-
pears to be a major regulator of ‘‘steady-state’’ granulopoiesis
and cooperates with PU.1 to ‘‘emergency’’ granulo-monocyto-
poiesis (Hirai et al., 2006; Jin et al., 2011). We observed a mild
but significant decrease of mRNA expression of PU.1, C/EBPb,
and C/EBPa in spleens and BM from Rorc1/>WT tumor
bearers, paralleled by decreased C/EBPb protein levels in
splenic PMN-MDSCs and M-MDSCs (Figure 6A). Importantly,
BM and spleens from Rorc1/>WT MN/MCA1 tumor bearers
displayed increased mRNA levels of the suppressor of cytokine
signaling-3 (Socs3) and the transcriptional co-regulator B cell
leukemia/lymphoma 3 (Bcl3) (Figure 6B), both potent inhibitors
of G-CSF-driven granulopoiesis (Croker et al., 2004; Kreisel
et al., 2011). In agreement with the IFN-g-mediated inhibition
of G-CSF-driven neutrophilia (Ulich et al., 1988), IFN-g induced
a strong increase of Socs3 and Bcl3 mRNA in splenic
PMN-MDSCs from Rorc1/ tumor bearers (Figure 6B, right).
Finally, in accordange with the decreased number of macro-
phages found in spleen and tumor of Rorc1/>WT chimeras
(Figure 6C), we observed a decreased number of IRF8-express-
ing CD11b+F4/80+CD115+ macrophages (Figure 6D), which
was confirmed by confocal microscopy in tumor tissues of
Rorc1/>WT chimeras (data not shown). As M-CSFR/CD115
(Qian and Pollard, 2010) is a marker of terminally differentiated
macrophages (Auffray et al., 2009), this result indicates that
RORC1 is required for the modulation of cell-fate switching fac-
tor(s) driving maturation of macrophages (Friedman, 2007).
RORC1 Controls Polarization of Myeloid Cells
M-CSFR signaling modulates macrophage survival and differen-
tiation (Qian and Pollard, 2010) and induces M2 macrophage
polarization, a condition supporting tumor progression (Manto-
vani and Sica, 2010). To evaluate RORC1 in the macrophage(C–E) In situ expression of IL-17A and RORC1 (RORg) within the hematopoietic
lymphoma (HL). Representative pictures show that both IL-17A (C) and RORC1 (E)
is not expressed by CD3+ cells in the BM (D).
(F) Lin cells were isolated from the BM of WT and Rorc1/mice and treated as
within the gate of viable cells (7-AAD-). Data shown are the mean ± SEM of two
(Student’s t test).
See also Figure S3.polarization, we analyzed the mRNA expression of prototypical
M1 and M2 genes in AD-PECs, cells displaying an intermediate
PEC versus a TAM phenotype and representing a good model
to study M1-M2 polarization in cancer (Sica et al., 2000; Tor-
roella-Kouri et al., 2009) from tumor-bearing WT>WT and
Rorc1/>WT chimeras. AD-PECs were isolated from tumor-
bearing WT>WT and Rorc1/>WT chimeras and treated with
100 ng LPS (M/L) or 200 U/ml IFN-g for 4 hr to induce M1 polar-
ization or exposed to LPS for 20 hr (L/M) to induce LPS-tolerant
M2-like polarization (Porta et al., 2009). In addition, spleen PMN-
MDSCs were stimulated 4 hr in vitro with IFN-g, LPS, or IFN-g
plus LPS. RORC1-deficient AD-PECs displayed enhanced
expression of M1 (IL-12p40, tumor necrosis factor alpha
[TNF-a], IL-1b) and decreased expression of M2 (IL-10, TGFb,
chitinase-3-like protein 3/Ym1) genes under M/L and L/M condi-
tions (Figure 7A). Simiarly, RORC1-deficient PMN-MDSCs
showed increased TNF-a and IL-1b mRNA levels and IL-1b
secretion in response to LPS/IFN-g (Figure 7B). Thus, RORC1
acts as negative regulator of M1 and promoter of M2 cytokine
genes. This observation was supported by the increased levels
of pro-inflammatory cytokines (TNF-a and IL-1b) and growth
factors (G-CSF, GM-CSF, and VEGF) in MN/MCA1 superna-
tants from Rorc1/>WT (Figure 7C), correlating with marked
splenomegalia observed in Rorc1/>WT chimeras bearing
the MN/MCA1 and MMTV-PyMT tumors (Figure 7D). Moreover,
we found increased splenic CD4+IFN-g+ and F4/80+TNF-a+
cells in tumor-free and tumor-bearing Rorc1/>WT mice
(Figure S5A), while total CD45+CD4+ cells decreased as
described (Figure S5A) (Harrington et al., 2005). In contrast,
tumor-infiltrating CD4+IFN-g+ and total CD45+CD4+ T cells
increased in Rorc1/>WT chimeras (Figure S5A). Furthermore,
F4/80+TNF-a+ macrophages increased in spleens and tumors
from Rorc1/>WT mice (Figure S5A). Supporting the inhibitory
role of RORC1, CD4+Foxp3+ T regulatory cells significantly
decreased in the spleen from Rorc1/>WT mice (Figure S5A).
Antagonistic Regulation of the Polymorphonuclear and
Monocytic Lineages
A decreased number of tissue macrophages in tumors from
Rorc1/>WT mice (Figure 3F) correlated with increased PMN-
MDSC infiltration (Figure 3E), suggesting that pathways leading
to terminal differentiation and M2 polarization of TAMs hamper
neutrophil accumulation in tumors. To prove this assumption,
we treated MN/MCA1-bearing WT mice with an anti-CSFR1
antibody (Ries et al., 2014), which significantly depleted the
CD11b+F4/80+CD115+ TAM population, co-expressing high
RORC1 levels (Figure 8A). Macrophage depletion was paralleled
by the inhibition of immature RORC1+ M-MDSCs and PMN-
MDSCs (Figure 8B) and increased tumor infiltration of mature
(C5ahighCD16/32high) (Figure 8C) RORC1Ly6Ghigh neutrophils
(Figure 8B). In agreement, RORC1 was highly expressed inBM parenchyma of patients undergoing BM biopsy for staging of Hodgkin’s
are produced by immature BM cells lining the endosteal niche, whereas IL-17A
indicated. The frequency of differentiated myeloid cell subsets was calculated
different experiments. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001
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Figure 5. CSF-, LPS-, and IL-1b-Mediated Induction of RORC1 in Innate Immune Cells
(A) Expression levels of GM-CSF, G-CSF,M-CSF, and IL-1b in theMN/MCA1 supernatants (TSN) from advanced disease were determined by ELISA. Data shown
are the mean ± SEM of three independent experiments.
(B) BM-MDSCs were left untreated or were treated with either TSN (MN/MCA1) or a combination of recombinant GM-CSF (40 ng/ml) and G-CSF (40 ng/ml) for
48 hr. Expression of IL-17A and RORC1 in M-MDSCs and PMN-MDSCs was evaluated by FACS analysis. Mean fluorescence intensity (MFI) ± SEM of three
representative experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(C) Expression and nuclear translocation of RORC1 in PECs exposed to IFN-g (200 U/ml), LPS (100 ng/ml), IL-1b (20 ng/ml), G-CSF (40 ng/ml), GM-CSF
(40 ng/ml), and M-CSF (40 ng/ml). After 72 hr of in vitro activation, PECs were stained with anti-RORC1 antibody (red) or irrelevant rat immunoglobulin G (IgG).
Nuclei were counterstained with DAPI (blue). Representative images are shown. Confocal microscopy analysis of RORC1 nuclear fluorescence intensity (nuclear
coefficient) is shown on the right. Mean ± SEM from three independent experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s
t test).
(D) MN/MCA1 tumor-bearing mice were treated with blocking antibodies against G-CSF, GM-CSF, M-CSFR/CSFR1, or isotype control antibody as indicated.
Data onM-MDSCs, PMN-MDSCs, andCD11b+F4/80+ cells in spleens frommicewith ADwithin the CD45+ gate (left) and primary tumor growth (center) are shown
as the mean ± SEM. The number of macroscopic lung metastases (right) is shown as the mean ± SD. A representative experiment with six mice/ group is shown.
Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
See also Figure S4.F4/80+/CD115+ macrophages, in comparison to reduced
RORC1 levels in Ly6Glow granulocytes and negativity in mature
inflammatory Ly6Ghigh granulocytes (Figure 8D), indicating that262 Cancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc.TAM infiltration is accompanied by infiltration of immature
MDSCpopulations, at theexpenseofmature neutrophils. Of rele-
vance, anti-M-CSF treatment resulted in a similar increase of
Figure 6. Influence of RORC1 on the Expression of Transcriptional Regulators of Myeloid Cell Maturation
(A) Total RNA from BM (left) and splenocytes (center) obtained from MN/MCA1-bearing WT>WT and Rorc1/>WT mice was analyzed by RT-PCR for the
expression of the C/EBPb, C/EBPa, and PU.1 transcription factors. Results are given as the fold increase over the mRNA level expressed by WT and are
representative of at least three different experiments. Mean percentages ± SEM of C/EBPb protein expression in M- and PMN-MDSC subsets in c-kitlow BM and
splenocytes fromWT>WT andRorc1/>WT tumor-bearing chimeras weremeasured by FACS analysis (right). Themean ± SD of three independent experiments
is shown.
(B) mRNA levels of Socs3 and Bcl3 in BM and splenocytes (left) or in unstimulated () and IFN-g-activated PMN-MDSCs (CD11b+Ly6G+) isolated from the spleen
(right) obtained from MN/MCA1-bearing WT>WT and Rorc1/>WT mice. Results are shown as the mean ± SEM from triplicate values.
(C) Splenic CD11b+F4/80+CD115+ macrophages (left) and CD11b+F4/80+CD115+ TAMs (right). Macrophage percentage in Rorc1/>WT chimeras (white bar) is
represented as relative value as compared to WT>WT chimeras (100%) (black bar). Results are shown as the mean ± SEM from triplicate values.
(D) The mean count ± SEM of IRF8+F4/80+ cells in spleens and MN/MCA1 from WT>WT and Rorc1/>WT chimeras analyzed within the CD11b+F4/80+ gate is
shown. The mean ± SEM of three independent experiments is shown. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).C5ahighCD16/32highmatureneutrophils in thespleen (FigureS6A),
indicating its systemic effects. These results are in agreement
with Figure 5D and together suggest a competition between the
monocytic and granulocytic commitment of myeloid precursors.
As mature RORC1PMN-MDSCs display a pronounced
inflammatory phenotype (Figure 7B), their inhibition most likely
contributes to maintaining the tumor-promoting microenviron-
ment. Furthermore, while M-CSF induced RORC1 expression
in splenic (data not shown) and medullar (Figure S4B) monocyte
precursors, treatment with anti-CSFR1 resulted in reducedmonocyte/macrophage precursors (population C + D) and
in increased granulocyte progenitors (population A + B) (Fig-
ure 8E). Supporting the role for reciprocal negative regulation
of monocytes/macrophages and granulocytes in cancer inflam-
mation, treatment with anti-G-CSF antibody increased the num-
ber of splenic F4/80+TNF-a+M1-likemacrophages, paralleled by
elevation of CD4+IFN-g+ Th1 cells (Figure 8F).
As the increase in CD4+IFN-g+ and F4/80+TNF-a+ cells
observed in Rorc1/ tumor-bearing mice was phenocopied
by the anti-G-CSF treatment of MN/MCA1 tumor-bearingCancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc. 263
Figure 7. Effects of RORC1 on Macrophage Polarization
(A) Total RNA from control (medium), activated (IFN-g), M1-activated (M/L), and M2-like LPS-tolerant (L/M) AD-PECs harvested from MN/MCA1 from WT>WT
(black bar) or Rorc1/>WT (white bar) chimeras were analyzed by RT-PCR for the expression of representative M1 genes (IL-12p40, TNF-a, and IL-1b) and M2
genes (IL-10, TGFb, and Ym1). Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001; n = 3 (Student’s t test). Results are representative of at least three different
experiments and are shown as the mean ± SEM from triplicate values.
(B) Total RNA from control (medium) and activated (IFN-g, LPS, or LPS+IFN-g) PMN-MDSCs obtained from the spleen from MN/MCA1-bearing WT>WT and
Rorc1/>WT chimeraswere analyzed by RT-PCR for the expression of representativeM1 genes (IL-1b and TNF-a). Secretion of IL-1b (pg/ml) was determined by
ELISA. Cells were activated as indicated for 24 hr. Results are given as the fold increase over the mRNA level expressed by untreated cells (medium) and are
representative of at least three different experiments; shown are the mean ± SEM from triplicate values. For ELISA, results are the average of three independent
experiments ± SD. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(C) Expression levels (pg/ml) of cytokines/growth factors in tumor supernatants (MN/MCA1) harvested fromWT>WT andRorc1/>WT chimeras. Results are the
average of three independent experiments ± SEM. Statistical analysis: *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test).
(D)Mean spleenweights (g)± SEM inMN/MCA1-bearing (n=10) andMMTV-PyMT (n= 6)mice.Statistical analysis: *p< 0.05, **p < 0.01, ***p< 0.001 (Student’s t test).
See also Figure S5.
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mice, we questioned whether G-CSFmight work through RORC.
To address this question, we treated WT and Rorc1/ tumor-
bearing mice with anti-G-CSF and monitored the expansion of
both CD4+IFN-g+ and F4/80+TNF-a+ cells. As a result, the anti-
G-CSF treatment significantly decreased RORC1 expression in
PMN-MDSCs and partially in M- MDSCs and F4/80+ macro-
phages (Figure S6B). Moreover, the increase of tumor-infiltrating
F4/80+TNF-a+ macrophages and CD4+IFN-g+ T cells in
response to anti-G-CSF, observed in WT mice, was significantly
reduced in Rorc1/ mice (Figure S6C), strengthening the
hypothesis that G-CSF works through the induction of RORC1.
Finally, to assess the role of myeloid-specific RORC1 in adaptive
immunity against cancer, we depleted CD4+ and CD8+ T cells in
both WT and Rorc1/ tumor-bearing mice. As a result, we
observed a significant increase of lung metastasis in Rorc1/
tumor-bearing mice treated with the anti-CD4/anti-CD8 anti-
bodies (Figure S6D), suggesting that the protumor activity of
RORC1 acts through both the innate and adaptive immunity.
DISCUSSION
We demonstrate that RORC1 fuels cancer-promoting inflam-
mation by enhancing survival and expansion of CD16/32low/
C5aRlow immature MDSCs, with reduced expression of M1 cyto-
kines (IL-1b and TNF-a) and increased suppressive activity, and
promoting terminal macrophage differentiation. Our study indi-
cates that RORC1 impinges on cancer-driven myelopoiesis by
suppressing negative (Socs3 and Bcl3) (Croker et al., 2004; Krei-
sel et al., 2011) and promoting positive (C/EBPb) (Hirai et al.,
2006) transcriptional regulators of ‘‘emergency’’ granulopoiesis,
while instating the expression of macrophage-specific tran-
scription factors IRF8 and PU.1 (Friedman, 2007). Depletion of
RORC1+F4/80+CD115+ TAMs with anti-CSFR1 antibody
enhanced the recruitment of mature (CD16/CD32high) RORC1
inflammatory neutrophils, with diminished expansion of imma-
ture RORC1+(CD16low/CD32low) PMN-MDSCs. This result, along
with the observed competition between the commitment of
myeloid precursors for the monocytic versus granulocytic line-
age, observed with the anti-G-CSF and anti-CSFR1 treatments,
respectively, may indicate that blocking M-CSF-dependent
myelopoiesis unleashes expansion and maturation of granulo-
cytic cells, which would favor the increase of tumor-infiltrating
neutrophils. These events deflect the inflammatory microenvi-
ronment to adverse the tumor, increasing infiltration of CD4+
IFN-g+ T cells and F4/80+TNF-a+ M1 polarized macrophages.
Our results indicate that high RORC1 expression acts as pro-
resolving mediator of myeloid inflammation and that antagonists
to RORC1 might hold the potential to prevent tumor-promoting
myeloid differentiation. We also report that IL-17 expression is
disjointed from RORC1 in the monocyte/macrophage lineage
(M-MDSCs and CD11b+F4/80+ TAMs). Wu et al. have recently
described that tumor-infiltrating inflammatory dendritic cells
activate IL-17-producing RORgt+ gdT17 cells to secrete IL-8,
TNF-a, and GM-CSF cells and sustain the subsequent intratu-
mor accumulation of immunosuppressive PMN-MDSCs in colo-
rectal cancer (Wu et al., 2014). Further, an inflammatory cascade
encompassing the IL-1b-mediated production by IL-17 in gdT
cells resulted in systemic G-CSF-dependent expansion of sup-
pressive neutrophils and formation of breast cancer metastasis(Coffelt et al., 2015). Our observation that IL-17 is selectively ex-
pressed, but not secreted by immature granulocyte/neutrophil
subsets, does not support a direct role of myeloid-cell-derived
IL-17 in the expansion of MDSCs during cancer development,
but rather indicates that IL-17A is a hallmark of immaturemyeloid
responses in cancer bearers. This notion is further supported by
the observation that expression of IL-17 and RORC1 localizes
within the immature myeloid cells precursor-rich areas lining
the bone trabeculae of BM biopsies from patients under diag-
nosis of Hodgkin’s lymphoma. Moreover, in contrast toRorc1/
BM transplantation, chimeric mice receiving the Il17a/BMhad
no defect in developing tumor-associated myeloid cells, in both
the BM and spleen (data not shown). It remains to be established
whether IL-17A expression by circulating MDSCs is dependent
on the disease stage, as we did not observe its expression in
blood from T2/T3 CRC patients.
Along with other reports, our observation highlights the rele-
vance of members of the nuclear receptor superfamily in regula-
tion of inflammation (Gerbal-Chaloin et al., 2013; Wittke et al.,
2004) and suggests RORC1 as central regulator of cancer asso-
ciated myelopoiesis and key driver of the protumor differentia-
tion of MDSCs and TAMs.
EXPERIMENTAL PROCEDURES
More-detailed procedures can be found in the Supplemental Experimental
Procedures.
Ethics Statement
The study was approved by the scientific board of Humanitas Clinical and
Research Center and designed in compliance with Italian governing law, EU
directives and guidelines, and the NIH Guide for the Care and Use of Labora-
tory Animals. Mice have beenmonitored daily and euthanized when displaying
excessive discomfort. Cancer patients were enrolled in the study after signing
Cancer Research Center Humanitas IRB-approved consent.
Mice
C57BL/6 mice were purchased from Charles River. RORC1 mutant mice
(B6.129P2(Cg)-Rorctm1Litt/J) (Sun et al., 2000) were donated by Dr. Dan Litt-
man (New York University). MMTV-PyMTmice (Guy et al., 1992) were donated
by Professor Guido Forni (University of Turin) andmated with C57BL/6 females
to obtain the F1 C57BL/6-MMTV-PyMT strain. IL-17A-deficient mice were
donated by Dr. Burkhard Becher (University of Zurich). All animal work was
conducted under the approval of the Humanitas Clinical and Research Center,
in accordance with Italian and EU directives and guidelines.
BM Transplantation
53 106 CD45.2 RORC1-deficient (Rorc1/), IL-17A/, or WT BM cells were
injected intravenously into 8-week-old lethally irradiated (two doses of 475
cGy) CD45.1 C57BL/6 WT male or C57BL/6-MMTV-PyMT female mice.
8 weeks later, BM engraftment was checked by staining of blood cells with
PerCP-conjugated CD45.1 antibody and PE-conjugated CD45.2 antibody
(BD Biosciences) and subsequent FACS analysis.
Tumor Models
105 murine fibrosarcoma (MN/MCA1) cells were injected intramuscularly in the
left hind limb. Tumor growth was monitored three times a week with a caliper,
starting from day 14. Themodels of chemically induce fibrosarcoma andmam-
mary tumor virus-polyoma middle T antigen (MMTV-PyMT) transgenic mice
are described in the Supplemental Experimental Procedures.
Cell Culture and Reagents
Lineage cell separation from BM, isolation of myeloid cells, and cell-culture
conditions are described in the Supplemental Experimental Procedures.Cancer Cell 28, 253–269, August 10, 2015 ª2015 Elsevier Inc. 265
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Mixed-Lymphocyte Reaction
Mixed-lymphocyte reaction was performed as previously reported (Larghi
et al., 2012) and as described in the Supplemental Experimental Procedures.
Patients
Ten patients with T2 or T3 CRC did not receive radiation or chemotherapy
before sample collection.
Flow Cytometry
Detailed conditions and antibodies used in flow cytometry analysis are
described in the Supplemental Experimental Procedures
Gating Strategy
Gating strategy for the identification of humanMDSCs, neutrophils, andmono-
cytes is described in the Supplemental Experimental Procedures.
Histopathological Analysis
Histopathological analysis was performed on BM and spleens from WT,
Rorc1/, and chimeric mice on sections routinely stained with H&E. Single-
and double-marker immunohistochemistry on mouse and human tissue spec-
imens were performed as previously reported (Tripodo et al., 2012) and are
described in detail in the Supplemental Experimental Procedures.
Confocal Microscopy
Confocal Microscopy was performed as previously reported (Moalli et al.,
2010) and as described in the Supplemental Experimental Procedures.
Statistics
Statistical significance was determined by a two-tailed Student’s t test
(*p < 0.05, ** p < 0.01, *** p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.07.006.
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(A) Mean counts ± SEM of CD115- and RORC1-expressing F4/80+ macrophages
treated tumor-bearing WT mice.
(B) Mean counts ± SEM of RORC1+ and RORC1 M-MDSC and PMN-MDSC su
(C) Mean fluorescence intensity (MFI) ± SEM for CD16/CD32 and C5aR expres
ant-CSFR1 antibody.
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